<DOC>
	<DOCNO>NCT00279435</DOCNO>
	<brief_summary>The purpose study compare efficacy , safety , pharmacokinetics , immunogenicity subject retreat visilizumab placebo response prior visilizumab study .</brief_summary>
	<brief_title>Study Visilizumab Versus Placebo Subjects With Intravenous Steroid-refractory Ulcerative Colitis Previously Responsive Visilizumab Study</brief_title>
	<detailed_description>The purpose study compare efficacy , safety , pharmacokinetics , immunogenicity subject retreat visilizumab placebo response prior visilizumab study . PDL BioPharma , Inc. formerly know Protein Design Labs , Inc .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>Males female , 18 year age older . Only 1 prior treatment course visilizumab ( placebo blind visilizumab study ) . Response ( define parent protocol ) intravenous steroidrefractory ulcerative colitis ( IVSRUC ) disease visilizumab placebo . Symptomatic worsening ( ie , increase ≥3 point MTWSI score ) subject 's best response parent study , MTWSI score ≥9 , sustain least 2 assessment perform least 1 week apart , confirmatory MTWSI ≥8 within 1 day prior randomization . CD4^+ Tcell count ≥ 200 cells/mcL screen protocol , ≥ 80 % subject 's screening baseline count prior enrollment parent study . Mayo assessment ( include flexible sigmoidoscopy ) perform trained , blind evaluate physician within 2 week prior randomization . Adequate contraception day consent 3 month last dose study drug . Negative serum pregnancy test . Negative Clostridium difficile test . Signed date informed consent , Health Insurance Portability Accountability Act ( HIPAA ) applicable . UC require immediate surgical , endoscopic , radiologic intervention . White blood cell count le 2.5 x 10^3/mcL ; platelet count le 150 x 10^3/mcL ; hemoglobin le 8 g/dL . Active , medically significant infection , particularly viral etiology , eg , know cytomegalovirus ( CMV ) colitis . This include incidence opportunistic infection within past 12 month . Live vaccination within 6 week prior randomization . Significant organ dysfunction , include cardiac , renal , liver , CNS , pulmonary , vascular , gastrointestinal , endocrine , laboratory abnormality , history myocardial infarction , coronary artery disease , congestive heart failure , arrhythmia within 6 month prior consent . History lymphoproliferative disorder ( LPD ) malignancy nonmelanoma skin cancer carcinoma situ cervix adequately treat within past five year . Seropositive infection human immunodeficiency virus ( HIV1 ) , hepatitis B virus ( HBV ) surface antigen , hepatitis C virus ( HCV ) . Pregnancy nursing . Treatment UC salvage drug ( include limit infliximab another antiTNFa drug , cyclosporine , tacrolimus [ FK506 ] , adalimumab , thalidomide , another experimental agent ) , therapy ( surgery , pheresis , affinity column ) since first course treatment study drug parent visilizumab study . Treatment investigational drug therapy within 60 day prior randomization . Nontherapeutic level chronic antiseizure medication subject history seizure . Any condition , investigator 's opinion , make subject unsuitable study participation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Intravenous , Steroid-Refractory , Ulcerative Colitis</keyword>
</DOC>